- Home
- EVOK vs RDHL Comparison
EVOK vs RDHL Comparison
Compare EVOK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- RDHL
- Stock Information
- Founded
- EVOK 2007
- RDHL 2009
- Country
- EVOK United States
- RDHL Israel
- Employees
- EVOK N/A
- RDHL N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- RDHL Health Care
- Exchange
- EVOK Nasdaq
- RDHL Nasdaq
- Market Cap
- EVOK 5.4M
- RDHL 3.9M
- IPO Year
- EVOK 2013
- RDHL N/A
- Fundamental
- Price
- EVOK $5.18
- RDHL $1.52
- Analyst Decision
- EVOK
- RDHL
- Analyst Count
- EVOK 0
- RDHL 0
- Target Price
- EVOK N/A
- RDHL N/A
- AVG Volume (30 Days)
- EVOK 432.5K
- RDHL 43.0K
- Earning Date
- EVOK 11-06-2025
- RDHL 09-05-2025
- Dividend Yield
- EVOK N/A
- RDHL N/A
- EPS Growth
- EVOK N/A
- RDHL N/A
- EPS
- EVOK N/A
- RDHL N/A
- Revenue
- EVOK $12,794,859.00
- RDHL $9,550,000.00
- Revenue This Year
- EVOK $57.38
- RDHL $381.91
- Revenue Next Year
- EVOK $59.57
- RDHL N/A
- P/E Ratio
- EVOK N/A
- RDHL N/A
- Revenue Growth
- EVOK 70.02
- RDHL 157.62
- 52 Week Low
- EVOK $1.94
- RDHL $1.06
- 52 Week High
- EVOK $12.32
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- EVOK 51.48
- RDHL 52.49
- Support Level
- EVOK N/A
- RDHL N/A
- Resistance Level
- EVOK $5.57
- RDHL $1.60
- Average True Range (ATR)
- EVOK 0.22
- RDHL 0.07
- MACD
- EVOK -0.25
- RDHL -0.02
- Stochastic Oscillator
- EVOK 92.17
- RDHL 95.00
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.